{
    "organizations": [],
    "uuid": "b91ad1f6a91513438689bc12bfdb6c37fae85208",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-herantis-pharma-h2-net-loss-at-eur/brief-herantis-pharma-h2-net-loss-at-eur-136700-idUSFWN1QK00Y",
    "ord_in_thread": 0,
    "title": "BRIEF-Herantis Pharma H2 Net loss at EUR 136,700",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 2 (Reuters) - Herantis Pharma Oyj:\n* ‍HERANTIS DOES NOT EXPECT ESSENTIAL REVENUES IN 2018​ * ‍CONTINUES TO INVEST IN ITS ONGOING DEVELOPMENT PROGRAMS IN SECONDARY LYMPHEDEMA AND PARKINSON’S DISEASE​\n* ‍MAIN OBJECTIVES FOR 2018 ARE LAUNCHING A PHASE 2 CLINICAL STUDY WITH COMPANY’S DRUG CANDIDATE LYMFACTIN®​\n* ‍MAIN OBJECTIVES FOR 2018 ARE COMPLETING PATIENT RECRUITMENT IN PHASE 1-2 CLINICAL STUDY WITH CDNF​\n* ‍DID NOT HAVE ESSENTIAL REVENUES IN 2017 OR IN CORRESPONDING PERIOD IN PREVIOUS YEAR​\n* H2 NET LOSS EUR 136,700 VERSUS LOSS EUR 1.8 MILLION YEAR AGO\n* PROPOSES ‍THAT NO DIVIDEND SHALL BE PAID FOR FINANCIAL PERIOD JANUARY 1-DECEMBER 31, 2017.​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-03-02T15:08:00.000+02:00",
    "crawled": "2018-03-03T17:29:27.001+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "herantis",
        "pharma",
        "oyj",
        "expect",
        "essential",
        "revenue",
        "invest",
        "ongoing",
        "development",
        "program",
        "secondary",
        "lymphedema",
        "parkinson",
        "objective",
        "launching",
        "phase",
        "clinical",
        "study",
        "company",
        "drug",
        "candidate",
        "objective",
        "completing",
        "patient",
        "recruitment",
        "phase",
        "clinical",
        "study",
        "essential",
        "revenue",
        "corresponding",
        "period",
        "previous",
        "h2",
        "net",
        "loss",
        "eur",
        "versus",
        "loss",
        "eur",
        "million",
        "year",
        "ago",
        "proposes",
        "dividend",
        "shall",
        "paid",
        "financial",
        "period",
        "january",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}